Hurco Companies First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.25 loss in 1Q 2024)
Revenue: US$46.4m (up 3.0% from 1Q 2024).
Net loss: US$4.32m (loss widened by 162% from 1Q 2024).
US$0.67 loss per share (further deteriorated from US$0.25 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hurco Companies shares are down 3.4% from a week ago.
You should learn about the 1 warning sign we've spotted with Hurco Companies.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
DoorDash purchases hospitality tech company SevenRooms
Online food ordering and delivery platform DoorDash has concluded the acquisition of the hospitality software provider SevenRooms. The US-based food delivery company states that the deal will bolster in-store sales, customer relationships and profitability for merchants by adding SevenRooms' CRM, reservations and guest experience tools to the DoorDash commerce platform. In May 2025, DoorDash agreed to acquire New York City-based SevenRooms for $1.2bn and UK competitor Deliveroo for £2.9bn ($3.8bn). SevenRooms will benefit from DoorDash's scale, resources and global reach. The company's leadership will join DoorDash to further develop its offerings. DoorDash vice-president of strategy and operations Parisa Sadrzadeh stated: 'We're building a platform that makes it easier for local businesses to grow — whether that's through delivery, pickup, reservations or in-person hospitality.' 'These capabilities reflect DoorDash's focus on empowering local businesses to deepen their relationships with customers, however they choose to connect - whether that's going out, ordering in or engaging through a merchant's own online stores. With SevenRooms, we will be able to keep supporting an open, partner-friendly ecosystem.' SevenRooms co-founder and head Joel Montaniel stated: 'We're excited to accelerate our mission to help hospitality operators around the world understand their guests, build deeper relationships and grow their businesses sustainably.' 'Together with DoorDash, we're providing restaurants and hospitality businesses with the tools to own their guest experience, grow their customer base and thrive both inside and outside their four walls. With shared core values, we're energised for our shared future as we bring continued innovation to market faster through a merchant-centric approach.' The acquisition comes shortly after DoorDash purchases ad tech startup Symbiosys for $175m, aimed at expanding its offsite advertising capabilities. Symbiosys offers a self-serve platform that allows advertisers to launch campaigns across channels including search, social, and display, while leveraging DoorDash's closed-loop measurement system. "DoorDash purchases hospitality tech company SevenRooms" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 hours ago
- Yahoo
Thai commerce minister confident of negotiating U.S. tariffs as low as 10%
BANGKOK (Reuters) -Thailand's commerce minister on Monday said his country would have trade talks with the United States and expressed confidence both sides could agree on good terms on tariffs, possibly as low as 10%. Pichai Naripthaphan told reporters he expected the talks would go well. He said Thai and U.S. officials would hold talks this week via video conference, he said, but said a date for talks at a ministerial level had not yet been set. He did not provide details on what would be discussed in the talks or why he thought the tariff level would be lowered from the 36% rate that the U.S. has said it will put on Thai goods. "Don't worry, we have everything prepared. The negotiation should be successful," he said. "We are in the process of detailing what is involved, but we can't tell you yet." Pichai also said export data in May were "good" and would be released on Wednesday. He also called for a weaker baht to support exports and tourism, saying a level of 37-38 per U.S. dollar was an appropriate level. The baht traded at 32.45 against the U.S. dollar on Monday.
Business Wire
6 hours ago
- Business Wire
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on or about July 9, 2025. We learned that Vivo Capital's counsel informed the paying agent that Vivo would challenge the dividend and asked the paying agent to withdraw from facilitating the distribution of the US$55.00 dividend declared by the SINOVAC Board to all valid shareholders. The SINOVAC Board has an obligation to answer this Petition on behalf of all SINOVAC common shareholders to stand up to the egregious actions of Prime Success. We expect to file our Opposition Brief today at 5:00 p.m. Atlantic Standard Time, followed by a hearing on Wednesday, June 18. We continue to be shocked by the self-serving, unnecessary actions by Advantech and Vivo Capital (together known as the 'Dissenting Investor Group') against SINOVAC, threatening the rightful dividend payment to all valid SINOVAC common shareholders. These incomprehensible actions are unacceptable to the SINOVAC Board because: The Dissenting Investor Group has already pocketed more than US$1.1 billion in dividends from SINOVAC's operating subsidiary, while all SINOVAC's valid shareholders received nothing. An amount equal to the aggregate amount of cash that would be payable under the US$55.00 per common share special dividend in respect of the 2018 PIPE shares has been set aside by the SINOVAC Board in an escrow account managed by an independent third party pending final resolution of the legal proceedings, which the Dissenting Investor Group initiated. Thus, there is no risk whatsoever that the Dissenting Investor Group's allocations of the dividend will not be paid if the courts ultimately decide in their favor regarding the PIPE shares. These new actions by the Dissenting Investor Group go against their assertions of their support of the US$55.00 dividend payment in their letters to shareholders and raises the question – how can you trust anything they say in their letters or press releases? The SINOVAC Board will continue to fight these frivolous lawsuits, all of which aim to accomplish one thing: to allow the Dissenting Investor group to double dip on dividends. We feel certain we will prevail quickly in this and other proceedings. The SINOVAC Board is on a mission to restore fairness and deliver value to ALL SINOVAC shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of filings, hearings and other litigation-related matters, all of which are difficult to predict and many of which are beyond the Company's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
